Treadwell Therapeutics Announces A Presentation at the 2022 SABCS Annual Meeting Featuring a Clinical Trial Update on CFI-402257, a Best-in-Class TTK inhibitor

/PRNewswire/ -- Treadwell Therapeutics, a clinical-stage biotechnology company developing novel medicines for highly aggressive cancers, today announced that...

Related Keywords

San Antonio ,Texas ,United States ,Canada ,Toronto ,Ontario ,Philippe Bedard ,Princess Margaret Cancer Centre ,University Of Toronto ,Henryb Gonzalez Convention Center ,San Antonio Breast Cancer Symposium ,Convention Center ,Associate Professor ,Staff Medical Oncologist ,Michael Tusche ,Phasei Trial ,Advanced Solid Tumors ,Negative Breast Cancer Expansion ,Treadwell Therapeutics ,Pharmaceuticals ,Health Care Amp Hospitals ,Medical Pharmaceuticals ,Clinical Trials Amp Medical Discoveries ,